Efficacy News and Research

RSS

AcelRx starts cancer breakthrough pain program

AcelRx Pharmaceuticals, Inc. has announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab product candidate for cancer breakthrough pain control.

22 Apr 2009

Scientists combine USB-based ultrasound probe technology with a smartphone

Computer engineers at Washington University in St. Louis are bringing the minimalist approach to medical care and computing by coupling USB-based ultrasound probe technology with a smartphone, enabling a compact, mobile computational platform and a medical imaging device that fits in the palm of a hand.

22 Apr 2009

Potential new drug blocks pathway of deadliest cancer

Scientists at Cancer Research Technology Ltd (CRT) will present exciting new findings showing that a potent and selective inhibitor of protein kinase D called CRT0066101, inhibits the growth of pancreatic tumours.

20 Apr 2009

Grapefruit juice boosts efficacy of drug rapamycin

In a small, early clinical trial, researchers at the University of Chicago Medical Center have found that combining eight ounces of grapefruit juice with the drug rapamycin can increase drug levels, allowing lower doses of the drug to be given.

20 Apr 2009

Nanoparticle delivery of a fully functioning copy of P53 tumor suppressor gene

Dr. Esther Chang describes the most recent developments in human trials of the first systemic, non-viral, tumor-targeted, nanoparticle method designed to restore normal gene function to tumor cells while completely bypassing normal tissue April 21 at an American Association of Anatomists (AAA) scientific session at Experimental Biology 2009 in New Orleans.

20 Apr 2009

Ardea Biosciences announces positive results from a phase 1 study of lead candidate for hyperuricemia and gout

Ardea Biosciences, Inc. has announced positive results from a Phase 1 study in normal, healthy volunteers of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and a pilot Phase 2a proof-of-concept study in gout patients of RDEA594's prodrug, RDEA806 (RDEA806 is converted to RDEA594 in the body).

20 Apr 2009

Study looks at effect of transcatheter arterial chemoembolization on liver function

Recently, it has been demonstrated that Transcatheter arterial chemoembolization (TACE) improves survival compared with best supportive care in meta-analyses of randomized trials and in two individual clinical trials.

20 Apr 2009

Could senna improve the quality of colonoscopy preparation with magnesium citrate?

Inadequate cleansing of the colon has an adverse effect on procedure time, safety, completion rate and diagnostic accuracy.

20 Apr 2009

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center.

20 Apr 2009

New minimally invasive surgery option for stomach cancer patients

A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) compares traditional "open" surgery to remove the stomach with laparoscopic gastrectomy - a minimally invasive procedure in which the surgeon removes the stomach while guided by a magnified image projected by a thin, lighted tube with a video camera at its tip, called a laparoscope.

15 Apr 2009

Hovione's TwinCaps inhaler in phase III trials for influenza

Hovione has announced that its licensee Daiichi Sankyo has informed that it intends to use Hovione's TwinCaps dry powder inhaler device in the launch of the compound CS-8958, an inhaled long-acting neuraminidase inhibitor active against the influenza virus.

15 Apr 2009

Discovery of a new target for novel HIV treatment strategy

The AIDS-causing HIV specifically counteracts the mechanisms of human cells that protect these against viral infections - a special viral protein marks protective cellular proteins for their rapid destruction and thus diminishes the cell's supply.

15 Apr 2009

OncoGel: New system for delivering chemotherapy for patients with esophageal cancer

Gastroenterologists at Rush University Medical Center are studying the safety and efficacy of a new system for delivering chemotherapy for patients with esophageal cancer, a rare, but deadly disease that attacks the throat.

15 Apr 2009

Topical bevacizumab therapy effective in treating corneal blood vessels growth that can cause blindness

Researchers at the Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute have concluded that short-term topical bevacizumab therapy reduces the severity of corneal neovascularization (formation of new blood vessels in the cornea that can create impaired vision or vision loss) without local or systemic adverse effects.

15 Apr 2009

Mycophenolate mofetil may be an alternative therapy for lupus nephritis

Lupus is a rare but serious disease that mainly affects women of child-bearing age and occurs when the body's immune system goes awry, damaging a variety of organs.

15 Apr 2009

$Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma$

Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma

Pharmacyclics, Inc. has announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

13 Apr 2009

Rapid test shows whether Alzheimer's drugs are hitting their target

A test developed by physician-scientists at Washington University School of Medicine in St. Louis may help assess more quickly the ability of Alzheimer's drugs to affect one of the possible underlying causes of Alzheimer's disease in humans, accelerating the development of new treatments.

12 Apr 2009

RNA interference can be used to silence genes selectively - potential for Huntington's disease therapy

Howard Hughes Medical Institute researchers have designed tiny RNA molecules that shut off the gene that causes Huntington's disease without damaging that gene's healthy counterpart, which maintains the health and vitality of neurons.

12 Apr 2009

FDA acts to avoid shortage of medically necessary opioid

The U.S Food and Drug Administration today amended its March 30, 2009, action warning manufacturers to stop the production and distribution of certain unapproved prescription opioids, to allow the continued marketing and distribution of one particular type of opioid -- a high concentrate morphine sulfate oral solution -- on an interim basis.

12 Apr 2009

Serentis begins trial with first-in-class SRD441 for eczema

Serentis, a privately owned biopharmaceutical company, announced that it has commenced patient recruitment in a Phase II clinical trial for atopic dermatitis (AD), a type of eczema.

9 Apr 2009

Efficacy News and Research

AcelRx starts cancer breakthrough pain program

Scientists combine USB-based ultrasound probe technology with a smartphone

Potential new drug blocks pathway of deadliest cancer

Grapefruit juice boosts efficacy of drug rapamycin

Nanoparticle delivery of a fully functioning copy of P53 tumor suppressor gene

Ardea Biosciences announces positive results from a phase 1 study of lead candidate for hyperuricemia and gout

Study looks at effect of transcatheter arterial chemoembolization on liver function

Could senna improve the quality of colonoscopy preparation with magnesium citrate?

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

New minimally invasive surgery option for stomach cancer patients

Hovione's TwinCaps inhaler in phase III trials for influenza

Discovery of a new target for novel HIV treatment strategy

OncoGel: New system for delivering chemotherapy for patients with esophageal cancer

Topical bevacizumab therapy effective in treating corneal blood vessels growth that can cause blindness

Mycophenolate mofetil may be an alternative therapy for lupus nephritis

Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma

Rapid test shows whether Alzheimer's drugs are hitting their target

RNA interference can be used to silence genes selectively - potential for Huntington's disease therapy

FDA acts to avoid shortage of medically necessary opioid

Serentis begins trial with first-in-class SRD441 for eczema

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News